Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype

被引:77
|
作者
Fornacon-Wood, Isabella [1 ]
Faivre-Finn, Corinne [1 ,2 ]
O'Connor, James P. B. [1 ,3 ]
Price, Gareth J. [1 ]
机构
[1] Univ Manchester, Div Canc Sci, Wilmslow Rd, Manchester M20 4BX, Lancs, England
[2] Christie Hosp NHS Fdn Trust, Dept Radiat Oncol, Manchester, Lancs, England
[3] Christie Hosp NHS Fdn Trust, Dept Radiol, Manchester, Lancs, England
关键词
Radiomics; Imaging biomarkers; Lung cancer; Personalized medicine; INTEROBSERVER DELINEATION VARIABILITY; LYMPH-NODE METASTASIS; FEATURE STABILITY; PATHOLOGICAL RESPONSE; HISTOLOGIC SUBTYPE; RADIATION-THERAPY; CT IMAGES; STAGE I; FEATURES; PREDICTION;
D O I
10.1016/j.lungcan.2020.05.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiomics has become a popular image analysis method in the last few years. Its key hypothesis is that medical images harbor biological, prognostic and predictive information that is not revealed upon visual inspection. In contrast to previous work with a priori defined imaging biomarkers, radiomics instead calculates image features at scale and uses statistical methods to identify those most strongly associated to outcome. This builds on years of research into computer aided diagnosis and pattern recognition. While the potential of radiomics to aid personalized medicine is widely recognized, several technical limitations exist which hinder biomarker translation. Aspects of the radiomic workflow lack repeatability or reproducibility under particular circumstances, which is a key requirement for the translation of imaging biomarkers into clinical practice. One of the most commonly studied uses of radiomics is for personalized medicine applications in Non-Small Cell Lung Cancer (NSCLC). In this review, we summarize reported methodological limitations in CT based radiomic analyses together with suggested solutions. We then evaluate the current NSCLC radiomics literature to assess the risk associated with accepting the published conclusions with respect to these limitations. We review different complementary scoring systems and initiatives that can be used to critically appraise data from radiomics studies. Wider awareness should improve the quality of ongoing and future radiomics studies and advance their potential as clinically relevant biomarkers for personalized medicine in patients with NSCLC.
引用
收藏
页码:197 / 208
页数:12
相关论文
共 50 条
  • [21] Advancing Personalized Cancer Medicine in Lung Cancer
    MacConaill, Laura E.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1210 - 1216
  • [22] Radiomics in Gastric Cancer: Another Step Toward Personalized Medicine
    Hu, Shudong
    Lu, Wenzheng
    ACADEMIC RADIOLOGY, 2025, 32 (01) : 132 - 133
  • [23] Lung Cancer - Genomics and Personalized Medicine
    Mahapatra, Anirban
    ACS CHEMICAL BIOLOGY, 2010, 5 (06) : 529 - 531
  • [24] The Clinical Future of Repetitive Transcranial Magnetic Stimulation and Depression: Separating Hope From Hype
    Pallanti, Stefano
    Schlaepfer, Thomas E.
    Lisanby, Sarah H.
    CNS SPECTRUMS, 2010, 15 (09) : 554 - 557
  • [25] Pathology and personalized medicine in lung cancer
    Kerr, Keith M.
    Loo, Peh Sun
    Nicolson, Marianne C.
    LUNG CANCER MANAGEMENT, 2013, 2 (01) : 35 - 46
  • [26] Targeting Cancer Stemness in the Clinic: From Hype to Hope
    Saygin, Caner
    Matei, Daniela
    Majeti, Ravindra
    Reizes, Ofer
    Lathia, Justin D.
    CELL STEM CELL, 2019, 24 (01) : 25 - 40
  • [27] Targeted therapy in the management of lung cancer: is there more hype than hope?
    Frances A. Shepherd
    Targeted Oncology, 2008, 3 : 131 - 133
  • [28] Targeted therapy in the management of lung cancer: is there more hype than hope?
    Shepherd, Frances A.
    TARGETED ONCOLOGY, 2008, 3 (03) : 131 - 133
  • [29] Recent advances in personalized lung cancer medicine
    Okimoto, Ross A.
    Bivona, Trever G.
    PERSONALIZED MEDICINE, 2014, 11 (03) : 309 - 321
  • [30] Germline mutations in lung cancer and personalized medicine
    Francesco Cetta
    Alessandra Renieri
    Elisa Frullanti
    Familial Cancer, 2018, 17 : 429 - 430